U‑Yin Pharmaceutical

U‑Yin Pharma’s EHT102 Gene Therapy Scores IND Approval Under NMPA’s 30‑Day Review for DFNB9 Hearing Loss

Shanghai U‑Yin Pharmaceutical (U‑Yin Pharma) announced that the National Medical Products Administration (NMPA) has approved...